Co-Administration of Darolutamide and Tacrolimus
Darolutamide can be co-administered with tacrolimus, but requires careful monitoring of tacrolimus levels and dose adjustments due to potential drug-drug interactions mediated through CYP3A4 and P-glycoprotein pathways.
Drug Interaction Mechanism
Darolutamide is predominantly metabolized by CYP3A4 and is a substrate for P-glycoprotein (P-gp) and BCRP 1. Tacrolimus is also extensively metabolized by CYP3A4 and is a P-gp substrate 2, 3. The FDA labeling for tacrolimus explicitly warns that when co-administering with CYP3A4 substrates and inhibitors, dose adjustments and frequent monitoring of tacrolimus whole blood trough concentrations are mandatory 2.
Clinical Evidence on Darolutamide's DDI Profile
The key finding is that darolutamide has demonstrated a low potential for clinically relevant drug-drug interactions with most CYP3A4 and P-gp substrates 1. In vitro studies showed that darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity, and mechanistic assessments indicated very low risk of clinically relevant DDIs via CYP inhibition 1.
Phase I clinical data confirmed this: co-administration of darolutamide with CYP3A4/P-gp substrates (midazolam and dabigatran etexilate) showed no effect or only minor effects 1. Furthermore, the ARAMIS trial population pharmacokinetic analysis of 388 patients found no significant effects on darolutamide pharmacokinetics despite frequent use of comedications with DDI potential 4.
Specific Monitoring and Management Strategy
Initial Co-Administration:
- Measure baseline tacrolimus whole blood trough concentrations before starting darolutamide
- Do not adjust tacrolimus dose preemptively based on the low DDI potential demonstrated in clinical studies 1, 4
Monitoring Schedule:
- Check tacrolimus trough levels within 3-5 days after initiating darolutamide 2
- Repeat tacrolimus levels weekly for the first month, then every 2 weeks for the second month
- Monitor for tacrolimus-associated adverse reactions: neurotoxicity (tremors, headache, mental status changes), nephrotoxicity (rising creatinine), hyperkalemia, and hypertension 2
Dose Adjustment Protocol:
- Adjust tacrolimus dose only if trough levels fall outside therapeutic range or if adverse reactions occur
- If tacrolimus levels increase: reduce tacrolimus dose by 25-50% and recheck levels in 3-5 days 2
- Monitor serum potassium, creatinine, and blood pressure at each tacrolimus level check 2
Special Considerations:
- QT prolongation risk: Both drugs can prolong QT interval. Obtain baseline ECG and monitor electrolytes (potassium, magnesium, calcium) periodically, especially if patient has other QT-prolonging medications 2
- Avoid strong CYP3A4 inhibitors/inducers when possible, as these will affect both medications 2
Important Caveats
The main drug interaction concern with darolutamide is with BCRP and OATP substrates (particularly statins), not with CYP3A4/P-gp substrates like tacrolimus 1. The rosuvastatin exposure increased 5.2-fold with darolutamide, but this was not seen with other substrate classes 1. This distinction is critical—tacrolimus falls into the category where darolutamide has shown minimal interaction potential.
The real-world ARAMIS trial data is particularly reassuring: despite 98.7% of patients using comedications (including frequent use of drugs with DDI potential), no clinically significant pharmacokinetic alterations of darolutamide were observed 4. The adverse event profile remained favorable even with extensive polypharmacy 4, 5.